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Abstract
The protein factor Glomulin (Glmn) is a regulator of the SCF (Skp1-CUL1-F-box protein) E3
ubiquitin-protein ligase complex. Mutations of Glmn lead to glomuvenous malformations.
Glmn has been reported to be associated with FK506-binding proteins (FKBP). Here we
present in vitro binding analyses of the FKBP—Glmn interaction. Interestingly, the previ-
ously described interaction of Glmn and FKBP12 was found to be comparatively weak.
Instead, the closely related FKBP12.6 and FKBP51 emerged as novel binding partners. We
show different binding affinities of full length and truncated FKBP51 and FKBP52 mutants.
Using FKBP51 as a model system, we show that two amino acids lining the FK506-binding
site are essential for binding Glmn and that the FKBP51-Glmn interaction is blocked by
FKBP ligands. This data suggest FKBP inhibition as a pharmacological approach to regulate
Glmn and Glmn-controlled processes.
Introduction
Glmn regulates the Skp1-Cullin-F-box complex, an E3-Ligase, which primes proteins for
proteasomal degradation [1]. One of the most studied examples of this E3 ligase family is
CRL1Fbw7 [2]. Glmn binds to this complex by intercalating between Cul1 and Rbx1. Hence-
forth, Glmn masks the interaction surface of Rbx1 towards the E2 ubiquitin-conjugating
enzyme Cdc34, leading to an inhibition of the ligase activity [3]. Glmn is thought to be a regu-
lator of ligase function and to prevent an overshooting ubiquitinylation reaction, which is
mediated by Rbx1-binding cullins. This was further supported by a crystal structure of the
Glmn-Cullin complex [3]. Later, an interaction of Glmn with cellular inhibitor of apoptosis
proteins 1 and 2 (cIAP1 and cIAP2), which regulate E3 ligases, was discovered [4]. Mutations
of the Glmn gene are the main cause of glomuvenous malformations [5–7] although the
underlying mechanism remains unclear and the link to E3 ligase regulation remains to be elu-
cidated. Additionally, most recently Glmn was associated with the infectious mechanism of
Shigella [4,8], where Glmn was claimed to be hijacked by a bacterial E3 ligase to promote
inflammation. Glomulin was initially described as FKBP Associated Protein (called FAP48 or
FAP68) [5,9]. In these studies, the FK506-binding proteins FKBP12 and 52 were identified as
interaction partners of Glmn in a yeast-2-hybrid system [9,10]. Furthermore, Pro219 of Glmn
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was suggested to be essential for the interaction with FKBP12 and FKBP52 [10]. More recently,
a link between FKBP51 and Glmn was described in a high-throughput interactome network
study [11]. During the last decade, FKBP51 emerged as a player in various pathologies. As
a key regulator of the hypothalamus-pituitary-adrenal axis, FKBP51 knockout leads to an
improved stress regulation in mice. Furthermore, FKBP51 knockout mice exhibit resistance to
diet-induced weight gain as well as experimentally induced chronic pain [12]. Selective ligands,
which discriminate FKBP51 over its close homologue FKBP52, were shown to positively influ-
ence stress-coping behavior, reduce weight gain and to ameliorate hypersensitivity states of
chronic pain. In neuronal cells, overexpression of FKBP51 retards neurite elongation during
neuronal differentiation, while knockdown and pharmacological inhibition increases it [13].
FKBP52 was shown to be essential in mice for the correct development of reproductive organs,
likely via its action on sex hormone receptors [14]. FKBP12 and FKBP12.6 bind to ryanodine
receptors and to receptors of the TGFβ family, where they are believed to suppress leaky signal-
ling [13]. To elucidate a potential regulation of Glmn by FKBPs and to increase our under-
standing of their molecular action modes we determined the binding affinities of Glmn
towards various FKBPs and the details of this interaction (Fig 1).
Methods
Overview of proteins
Genes encoding codon optimized His-FKBP51FK1-MonoCys (aa1-140, C103A, C107I,
E140C) and His-FKBP12-MonoCys (C23V / E108C) were obtained from GeneArt1 (Thermo-
Fisher Scientific) and subcloned into pET30b expression vector. The mutated cysteines are
neither located within the binding site nor conserved between FKBP51, FKBP52 and FKBP12.
The corresponding internal cysteines were mutated in order to ensure labelling at only a single,
C-terminal site by exchanging Glu140 in FKBP51FK1 and Glu108 in FKBP12, respectively.
His-FKBP51FK1 (aa16-140) in pET30b expression vector; His-FKBP51FK1, His-
FKBP51FK1 (F67V), His-FKBP51FK1 (FD67/68DV), His-FKBP52FK1, His-FKBP51-Strep,
His-FKBP52-Strep, His-FKBP12 and His-FKBP12.6 in pProEx-HTA and GST-Glmn in pGex
expression vector were used as previously described [3,15–19].
Protein purification
All used proteins were expressed in E.coli BL21(DE3) cells. The cultures were grown to an
OD600 = 0.5, induced with 600 μM IPTG, and grown for 4 h at 37 ˚C (Mono-Cys variants for
4 h at 30 ˚C and GST-Glmn at 18 ˚C overnight). Cultures were spun down, resuspended in
lysis buffer (20 mM HEPES, 200 mM NaCl, 200 mg/mL lysozyme, 2.5 mM PMSF, 0.1 mg/mL
DNAse I, pH 8.0) and subjected to sonication. After that, the lysate was centrifuged (35k xg, 4
˚C, 30 min). Nickel-NTA beads (Machery Nagel) or Glutathion beads (GE Healthcare) were
equilibrated in washing buffer (20 mM HEPES, 200 mM NaCl, pH 8.0), added to the superna-
tant and incubated for 2 h on a rolling device at 4 ˚C. Afterwards, the beads were spun down
(100 xg, 2 min), the supernatants were removed and the beads were washed two times in wash-
ing buffer. The beads were transferred to a column (Bio-Rad) and washed again. Elution was
performed with elution buffer (20 mM HEPES, 200 mM NaCl, pH 8.0, 300 mM imidazole or
10 mM glutathione, respectively). The elution progress was monitored via a qualitative Brad-
ford assay. Protein-containing fractions were pooled, centrifuged (14k xg, 4 ˚C, 20 min) and
the supernatant was subjected to size exclusion chromatography (FPLC buffer: 20 mM Hepes,
20 mM NaCl, 5%(v/v) glycerol, pH 8.0). Resulting protein fractions were quantified via molec-
ular extinction at 280 nm, frozen in liquid nitrogen and stored at -80 ˚C. All buffers used for
the purification of Mono-Cys mutants and GST-Glmn additionally contained 5 mM DTT.
FKBP-Glmn interactions
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Protein labelling
FKBP51FK1-MonoCys and FKBP12-MonoCys were dialysed for 5 cycles in a Dialyse Slide-
A-Lyzer 3.5k MWCO (ThermoFisher) in 20 mM HEPES, 20 mM NaCl, 5%(v/v) glycerol, 10
mM TCEP pH 8.0 to remove DTT. The protein was added to equilibrated Ni-NTA. After 2 h,
a 20-fold molar excess of fluorescein-maleimide (Toronto Research Chemical) was added and
incubated for 2 h. The mix was added to a column (Bio-Rad) and washed with buffer (20 mM
HEPES, 20 mM NaCl, 5% (v/v) glycerol, pH 8.0, 5 mM DTT) until the flowthrough became
colorless. Elution was performed with elution buffer (20 mM HEPES, 200 mM NaCl, pH 8.0,
300 mM imidazole). The elution was stopped as the eluate became colorless. In order to
remove remaining unreacted fluorescein-maleimide, the labelled protein was dialysed for 5
cycles in a Dialyse Slide-A-Lyzer 3.5k MWCO (ThermoFisher) in 20 mM HEPES, 20 mM
NaCl, 5% glycerol, 5 mM DTT, pH 8.0. Protein concentration was determined by measuring
OD280 and OD495 (calculation protocol by ThermoFisher).
Labelled protein activity assay (destructive FRET)
The TAMRA-labelled bicyclic ligand FK[4.3.1]-16g [20] (S1A Fig) was serially diluted in 15
steps to a concentration series ranging from 25 μM to 1.5 nM in DMSO. 1 μL of each dilution
step was added to a black 384 well plate (Corning 3575). 50 μL of a 5 nM solution of Fluores-
cein-5-Maleimide (5-MF)-labelled protein in FP-Assay buffer (20 mM HEPES, 0.002%(v/v)
Triton X-100, pH 8.0) were added to each well. Fluorescence (Ex: 485 nm, Em: 520 nm) was
measured with a Tecan Genios Pro plate reader. Experiments were performed in triplicates.
Mean values and standard deviations were plotted. Curves were fitted via a one-site-ligand
depletion curve (Y = A / E � 0.5 �(X + E + 1 / K—sqrt (sqrt (X + E + 1 / K)—4 � E � X))+B)
using GraphPad Prism 6. Figure tables show K values and their respective standard deviation.
Active site titration of FKBPs
All unlabelled FKBPs were quantified by active site titrations [15]. Briefly, proteins were seri-
ally diluted in 15 steps in FP-assay buffer and mixed 1:1 with a 50 nM solution of the TAMRA-
Fig 1. HTRF assay setup. Characterization of the binding of Glmn and the FK1 domain of FKBP51� (MonoCys mutant covalently labelled with
Fluorescein-5-Maleimide = 5-MF) via a homogeneous time-resolved fluorescence resonance energy transfer (HTRF) assay. Molecules that bind to
the binding sites on FKBPs or Glmn can be quantified in a competitive setup. HIS = polyhistidine-tag, GST = glutathione S-transferase tag.
https://doi.org/10.1371/journal.pone.0221926.g001
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labelled bicyclic ligand FK[4.3.1]-16g [20] (S1A Fig) in FP-Assay buffer in a black 384 well
plate (Corning 3575). Fluorescence polarization was measured with a Tecan Genios Pro plate
reader, plotted against the UV concentration and subjected to a four-parameter fit using
GraphPad Prism6: Y = Bottom + (Top—Bottom) / (1 + (x/EC50)^(-Hillslope)). Experiments
were performed in either duplicates or triplicates. Mean values and standard deviations were
plotted. Concentration of active protein was calculated: cAST = ((0.5x cTracer + KD) / EC50) x
cUV. The results of the active site titrations were used for the HTRF assays and can be found in
S1 Table.
HTRF-assay
Equal parts (20 μL) of 120 nM FKBP51FK-MonoCys-Fluorescein (FKBP51FK1-5-MF),
competitor solution (unlabelled FKBPs or FKBP ligands at various concentrations), 120 nM
GST-Glmn and 3.2 nM MAb Anti GST-Tb cryptate (61GSTTLA, Cisbio) in HTRF buffer (20
mM HEPES, 5%(v/v) glycerol, 20 mM NaCl, 10 mM DTT, pH 8.0) were consecutively added
to a black 384 well plate (Corning 3575) and incubated at room temperature for 1h. Fluores-
cence (Ex: 485 nm, Em: 520 / 620 nm) was measured with a Tecan Genios Pro plate reader in
HTRF mode (lag time: 150 μs, integration time: 500 μs). The signal of 520 nm was normalized
to the signal of 620 nm as a reference. Experiments were performed in triplicates. Mean values
and standard deviations were plotted. Curves were fitted via a four-parameter fit: Y = Bottom
+ (Top-Bottom)/(1+10^((LogIC50-X)�HillSlope)) using GraphPad Prism 6. Figure tables
show IC50 values and their respective standard deviation.
Results
To quantify the Glmn-FKBP interactions we developed a protein-protein interaction assay
with purified proteins. Towards this goal, we chose FKBP12 and the FK506-binding domain of
FKBP51 as a well described and structurally very well understood representatives of the FKBP
family. We generated labelled mutants of FKBP51FK1 and FKBP12 containing a single cyste-
ine at their respective C-terminus with Fluorescein-5-Maleimide. In order to confirm the
activity of the labelled proteins, a destructive FRET assay was performed using a TAMRA-
labelled FKBP ligand as FRET acceptor [20]. The fluorescein label emission of both proteins
was dose-dependently quenched upon the titration with the FRET acceptor (Fig 2A). Impor-
tantly, the apparent affinities were very similar compared to the affinities, which were obtained
for this tracer for the wild type protein constructs [20], suggesting that the labelled proteins
were fully binding-competent and that the mutations of the internal cysteines did not compro-
mise the principal binding capacity of the FK506-binding site.
To set up a direct FKBP-Glmn protein-protein binding assay, both labelled FKBPs were
incubated with increasing amounts of GST-tagged Glmn and a Terbium-cryptate-linked anti-
body against this tag. Surprisingly, an HTRF signal was only obtained with the FK1 domain of
FKBP51 but not with FKBP12, when using the same batch of protein preparation as used for
the destructive FRET assay (Fig 2B).
Based on these results, 30 nM FKBP51FK1-5-MF and 30 nM GST-Glmn were chosen to set
up a competitive HTRF assay.
In the literature, Glmn has been described as an interactor of FKBP52 and FKBP12 [9,10].
Using the competitive HTRF setup, we titrated various unlabelled FKBPs (Fig 3). Prior to
these experiments, all used FKBPs were characterized via active site titration or isothermal
titration calorimetry to confirm the concentration of binding-competent proteins after purifi-
cation (shown in S2 and S3 Figs)[15,20].
FKBP-Glmn interactions
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We observed that the FK1 domains of FKBP51 and FKBP52 as well as FKBP12.6 competed
for Glmn with comparable potency (Fig 3). Notably, full-length FKBP52 competed for Glmn
binding approximately 19-fold better than its FK1 domain, indicating additional binding con-
tacts exhibited by its other domains. The difference between the isolated FK506-binding
domain and full-length protein was much weaker for FKBP51 (4-fold), indicating that the FK2
and TPR domain of FKBP51 also contact Glmn but that these interactions are weaker com-
pared to FKBP52.
Fig 2. Development of an HTRF-based assay for binding of FKBPs and Glmn. (A) Fluorescein-labelled FKBP51FK1 and FKBP12 bind to the TAMRA-labelled
FKBP ligand FK[4.3.1]-16g as observed by a destructive FRET. Corresponding KD values are indicated below and represent mean values and standard deviation
of three independent dilution series; (B) Titration of GST-Glmn to 30nM Fluorescein-labelled protein in the presence of 0.8 nM Anti GST-Tb cryptate followed
by HTRF readout (Ex: 485 nm, Em: 520 / 620 nm).
https://doi.org/10.1371/journal.pone.0221926.g002
Fig 3. Different unlabelled FK1 domains and FKBPs compete for Glmn binding. (A), FKBP52FK1, FKBP12 and FKBP12.6; (B) FKBP52FL (full length),
FKBP51FL (full length), FKBP51FK1 (aa 16–140). Corresponding IC50 values are indicated below and represent mean values and standard deviation of three
independent dilution series.
https://doi.org/10.1371/journal.pone.0221926.g003
FKBP-Glmn interactions
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Even more interesting was the observed difference between FKBP12 and FKBP12.6, which
both comprise a single, highly homologous FK506 binding domain. While FKBP12.6 binds
Glmn with similar affinity as the full-length FKBP51, FKBP12 competed for Glmn-binding
only very weakly. However, the poor competition of FKBP12 is in line with the inactivity of
the labelled FKBP12 in the direct FRET assay (Fig 2B).
To further probe the FKBP51-Glmn interaction, we tested a competition of small molecule
FKBP ligands in the competitive HTRF assay (Fig 4). The natural ligand FK506 as well as the
potent bicyclic analog [4.3.1]-16j [20] efficiently blocked the FKBP51-Glmn interaction, sup-
porting the notion that the FK506-binding pocket is likely the major Glmn binding site in
FKBP51. However, at this point, we cannot exclude that the compounds FK506 and FK[4.3.1]-
16j block the Glmn-FKBP interaction through moieties extruding from the binding pocket,
which might sterically interfere with Glmn binding.
To confirm the FK506-binding site in FKBPs as the major Glmn binding pocket, we investi-
gated known FK506-binding site mutations using FKBP51 as a model system. Specifically, we
tested the FKBP51FK1 mutants carrying an F67V [21,22] or an FD67/68DV [23] double muta-
tion, which line the active site of the FK506-binding pocket. The F67V mutation is known to
retain anti-neuritotrophic activity as well as binding to bicyclic FK506 analogs [24], while the
FD67/68DV double mutation was shown to abolish the peptidyl-prolyl isomerase activity of
FKBP51 [23,25–27]. The affinity of the fluorescent tracer TAMRA-labelled bicyclic ligand FK
Fig 4. The unlabelled FKBP ligands FK506 and FK[4.3.1]-16j compete for Glmn binding in the HTRF assay. Corresponding IC50 values are indicated below
and represent mean values and standard deviation of three independent dilution series.
https://doi.org/10.1371/journal.pone.0221926.g004
FKBP-Glmn interactions
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[4.3.1]-16g was only minimally shifted by the F67V mutation, while the binding capacity of
the FD67/68DV double mutation was substantially compromised (Fig 5A). The integrity of all
FKBP51 mutant batches was confirmed by active site titration by fluorescence polarization or
isothermal calorimetry (S3 Fig).
In the competitive HTRF assay, the F67V mutant exhibited slightly reduced affinity to
Glmn, whereas the competition for the FD67/68DV double mutant was very weak (Fig 5B).
This indicates that especially D68 seems to be important for the binding of Glmn to FKBP51.
Interestingly, in this assay we also tested complete FK1(1-140aa) in direct comparison to the
previously used N-terminally truncated FK1(16-140aa) construct [18] and observed that the
presence of the N-terminus did not reduce competitive binding of FKBP51FK1.
Discussion
Within the last years, Glmn emerged as a regulator of the E3 ligase Skp1-Cullin-F-box-com-
plex. It is connected to this complex via Cul1 and Rbx1 [3]. Both Glmn knockdown and
knockout cells exhibit altered levels of E3 ligase targets [1]. Little is known regarding the regu-
lation of Glomulin itself. FKBPs, especially FKBP52 and FKBP12, were reported to bind to
Glmn but comprehensive studies on these interactions are missing. Here, we report that Glmn
is able to bind all tested FKBPs, including FKBP51 and FKBP12.6.
The finding that FKBP12 binds Glmn much weaker than the highly homologous 12.6 was
highly unexpected. Both small FKBPs are well described for their regulation of ryanodine
receptors (RyR), which mediate calcium influx during muscle contraction. Different affinities
and selectivity for FKBP12 and FKBP12.6 towards RyR1 and RyR2 have been reported
(recently reviewed [13]). FKBP12 and 12.6 differ in 18 amino acids of which three residues
(Gln31, Asn32, and Phe59 in FKBP12.6) were sufficient to reverse the selectivity towards RyR2
[28]. Similar swapping experiments may identify the residues underlying the affinity differ-
ences of FKBP12 and FKBP12.6.
Surprising differences in Glmn binding were also found for the highly homologous large
FKBPs FKBP51 and FKBP52. The higher affinity of FKBP52 has to reside within the FK2 and
TPR domains, which seem to form additional contacts with Glmn that are much more produc-
tive compared to FKBP51. Future truncation and domain swapping experiments between full-
length FKBP51 and FKBP52 will be necessary to further elucidate the role of the FK2 and TPR
domains of FKBP51 and FKBP52. Based on crystallographic data, FKBP52 can exhibit two
different confirmations: one is similar to FKBP51 and a second conformation where its FK1
domain is rotated by 180˚ relative to its FK2 domain [19]. This second confirmation might
allow additional contacts with Glmn that are unavailable for FKBP51.
In our studies, we identified FKBP52 as a preferred Glmn binding partner over FKBP51.
These data predict FKBP52-Glmn complexes to dominate over FKBP51-Glmn complexes
unless the latter is highly overexpressed such as suggested in adipocytes [29,30] or skeletal
muscle [31,32]. Likewise, our data predict that FKBP12.6-Glmn complexes to dominate over
FKBP12-Glmn complexes. The dominant interaction FKBP interaction partner, of course,
depends also on the relative expression levels of FKBPs, which is cell-type and context-
dependent.
While the strongly reduced activity of the FD67/68DV mutation points to the requirement
of an intact FK506-binding pocket and additionally also to a functional role to the PPIase
activity, it is possible that these mutations alter the structure of the FKBPs in more global
ways that eventually impinge on a reduced capacity to bind to Glmn. In this study, the
FK506-binding domain of FKBP51 was used as a model system and functional tracer to allow
competitive studies. Due to the high homology within the FKBP family, it seems likely that the
FKBP-Glmn interactions
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Fig 5. Characterization of FKBP51 active site mutants. (A) FKBP51FK1 (1–140) and mutants F67V bind to the high-affinity
TAMRA-labelled tracer FK[4.3.1]-16g with similar affinity in the fluorescence binding assay, while binding of the mutant FD67/68DF
is compromised. (B) FKBP51 mutants F67V bind with slightly and FD67/68DV with substantially reduced affinity to GST-Glmn in the
competitive HTRF assay. KD or IC50 values are indicated below and represent mean values and standard deviation of three
independent dilution series.
https://doi.org/10.1371/journal.pone.0221926.g005
FKBP-Glmn interactions
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FK506-binding site is the major binding site for Glmn for other FKBPs as well. However, it is
possible that the FK506 binding site mutations behave differently in the context of the full-
length protein. Numerous, high-quality ligands for FKBPs are available [20,33–36], some with
substantial FKBP-subtype selectivity [21,37–39]. This suggests that the putative regulatory role
of FKBPs on Glmn can be pharmacologically blocked with drug-like molecules.
Our findings may also be relevant for the mechanism of action of FKBP5,1 which recently
has raised substantial interests as a risk factor for stress-related diseases, obesity/diabetes,
and chronic pain. FKBP51 has been suggested to interact with numerous protein partners but
the detailed biochemical mode of actions is so far elusive. To our knowledge, this study pro-
vides the first biochemically detailed characterization of a purified protein binding partner of
FKBP51.
Collectively, these findings support the hypothesis that FKBPs might represent a new layer
of regulation of Glmn and that different FKBPs can differentially regulate the function of
Glmn. Taken together, our work defines FKBPs as high-affinity interactions partners of Glmn
that may offer a pharmacological perspective to manipulate Glmn-related disorders.
Supporting information
S1 Fig. (A) Structure of TAMRA labelled tracers / quenchers FK[4.3.1]-16g and (B) 2b.
(TIF)
S2 Fig. Active site titrations of all used FKBPs except for FKBP51FK1 (1–160) FD67/
68DV. Assays were performed in duplicates or triplicates with 50 nM TAMRA-FK[4.3.1]-16g
tracer. Graphs values of independent dilution series. Active protein concentrations were calcu-
lated by cAST = ((0.5x cTracer + KD) / EC50) x cUV.
(TIF)
S3 Fig. ITC for FKBP51FK1 (1–160) FD67/68DV. To assess the binding-active fraction of
the FKBP51FK1 (1–160) sample an ITC experiment was carried out. A 20 μM solution of the
protein in 20 mM HEPES pH 8.0, 20 mM NaCl, 5% glycerol and 1% DMSO was placed in the
sample cell of a PEAQ-ITC (Malvern) and a 200 μM solution of the ligand FK[4.3.1]-16h in
the same buffer was filled into the syringe. After equilibration to 25 ˚C the ligand was titrated
stepwise into the protein solution. The resulting data was analyzed using the provided ITC
analysis software and fitted to a one-site binding model yielding the binding enthalpy (ΔH) the
Kd-value and the binding stoichiometry (n).
(TIF)
S1 Table. Overview of used competing proteins listing concentrations determined via
active site titration, isothermal titration calorimetry and UV absorption as well as the KD
values of the tracer FK[4.3.1]-16g to the respective protein.
(XLSX)
S1 File. Primary data.
(XLSX)
S2 File. Primary data of the supplemental information.
(XLSX)
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